Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (11523)	11/20/1997 1:27:00 AM
From: Proton	Read Replies (2) \| Respond to of 32384

Re: Novo's Type II Diabetes Agent New advisory panel recommendation: dljdirect.com ... fresh from an expedited review! Henry recently posted a piece from October, 1996 about Novo Nordisk's collaboration with Takeda. Or is this the result of the licensing of Insulinotropin from Scios? The only other mention of this I saw on SI was someone who had Novartis and Novo Nordisk mixed up. It's beginning to feel a bit crowded in the Type II room. Help a software jock out understand why we should be more excited abou Targretin later over <<< now? Pý (apologies for my attempt to get on topic, here) p.s. Found out about this from TheStreet.com's "After-hours Report."